Format

Send to

Choose Destination
Surv Ophthalmol. 2016 Jan-Feb;61(1):33-50. doi: 10.1016/j.survophthal.2015.08.005. Epub 2015 Aug 29.

Retinal abnormalities in β-thalassemia major.

Author information

1
Department of Ophthalmology, F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania, USA; Department of Ophthalmology, Albany Medical College, Albany, New York, USA.
2
Department of Ophthalmology, F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania, USA. Electronic address: jdunaief@mail.med.upenn.edu.

Abstract

Patients with beta (β)-thalassemia (β-TM: β-thalassemia major, β-TI: β-thalassemia intermedia) have a variety of complications that may affect all organs, including the eye. Ocular abnormalities include retinal pigment epithelial degeneration, angioid streaks, venous tortuosity, night blindness, visual field defects, decreased visual acuity, color vision abnormalities, and acute visual loss. Patients with β-thalassemia major are transfusion dependent and require iron chelation therapy to survive. Retinal degeneration may result from either retinal iron accumulation from transfusion-induced iron overload or retinal toxicity induced by iron chelation therapy. Some who were never treated with iron chelation therapy exhibited retinopathy, and others receiving iron chelation therapy had chelator-induced retinopathy. We will focus on retinal abnormalities present in individuals with β-thalassemia major viewed in light of new findings on the mechanisms and manifestations of retinal iron toxicity.

KEYWORDS:

PXE-like syndrome; beta-thalassemia major; deferiprone; desferrioxamine retinopathy; hepcidin; iron; iron overload; pseudoxanthoma elasticum

PMID:
26325202
PMCID:
PMC4690783
DOI:
10.1016/j.survophthal.2015.08.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center